CDK12 and prostate carcinoma: Integrating our experimental findings with clinical data, we hypothesize that CDK12 deficiency may not promote the malignant phenotype of prostate cancer by affecting cell proliferation but rather by making tumour cells more resistant to current therapies through metabolic reprogramming and other mechanisms, leading to a worse prognosis.